Opioid-induced constipation (OIC) is common and can significantly affect quality of life. Naloxegol and methylnaltrexone are peripherally acting µ-opioid receptor antagonists (PAMORAs) which are effective for the management of OIC. We report on a case in the palliative care setting where a patient with established OIC had an inadequate response to naloxegol but an effective and immediate response to methylnaltrexone at the dose recommended for her weight. This is the first reported case of two PAMORAs used concomitantly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmjspcare-2019-002172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Naloxegol rescue with methylnaltrexone highly effective.
BMJ Support Palliat Care
September 2020
Palliative care, St Luke's Hospice, Sheffield, UK.
Opioid-induced constipation (OIC) is common and can significantly affect quality of life. Naloxegol and methylnaltrexone are peripherally acting µ-opioid receptor antagonists (PAMORAs) which are effective for the management of OIC. We report on a case in the palliative care setting where a patient with established OIC had an inadequate response to naloxegol but an effective and immediate response to methylnaltrexone at the dose recommended for her weight.
View Article and Find Full Text PDFPharmacological Treatment of Opioid-Induced Constipation Is Effective but Choice of Endpoints Affects the Therapeutic Gain.
Dig Dis Sci
January 2019
Section of Gastroenterology, George E. Wahlen VAMC, 500 Foothill Dr, Salt Lake City, UT, 84103, USA.
Background: Widespread opioid use has led to increase in opioid-related adverse effects like constipation. We examined the impact of study endpoints on reported treatment benefits.
Methods: Using MEDLINE, EMBASE, and ClinicalTrials.
Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
J Pain Symptom Manage
February 2018
School of Oral Health, College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji.
Context: Opioid-induced constipation is a common problem associated with chronic use of opioid analgesics.
Objectives: The objective of this study was to compare available interventions for the treatment of opioid-induced constipation, using principles of network meta-analysis.
Methods: Electronic databases were searched for randomized controlled clinical trials evaluating drugs used in opioid-induced constipation.
Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
Pharmacoeconomics
February 2017
Evidera Inc., Metro Building 6th Floor, 1 Butterwick, London, W6 8DL, UK.
Background And Objectives: Opioid-induced constipation (OIC) is the most common adverse effect reported in patients receiving opioids to manage pain. Initial treatment with laxatives provides inadequate response in some patients. Naloxegol is a peripherally acting µ-opioid receptor antagonist used to treat patients with inadequate response to laxative(s) (laxative inadequate responder [LIR]).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!